Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study - Ghofrani, H-A; Simonneau, G; D'Armini, A M; MERIT study investigators (Lancet Respir Med, 2017)